



## Pharvaris to Participate in BioCapital Europe

March 4, 2021

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

### **Participation Details:**

**Title:** "Shaping the New Biotech Reality – Key Lessons from COVID" Panel Presentation

**Date/Time:** March 10, 2021, 18:30 CET (12:30 p.m. EST)

**Title:** Pharvaris Corporate Presentation

**Date/Time:** March 11, 2021, 14:50 CET (8:50 a.m. EST)

The virtual presentation will be available for 30 days on the Pharvaris website at <https://ir.pharvaris.com/news-events/events-presentations>.

### **About Pharvaris**

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit <https://pharvaris.com/>.

### **Investor Contact**

Chad Rubin, Solebury Trout

[crubin@soleburytrout.com](mailto:crubin@soleburytrout.com)

### **Media Contact**

Maggie Beller, Russo Partners, LLC

[maggie.beller@russopartnersllc.com](mailto:maggie.beller@russopartnersllc.com)

+1-646-942-5631